Search bioRxiv⌕ Search

Biology subjects

Clarke, M. A.

Publications and source records attributed to Clarke, M. A..

4 recordsLinked to original sources

MAGELLAN: Automated Generation of Interpretable Computational Models for Biological Reasoning

Computational models have become essential tools for understanding signalling networks and their non-linear dynamics. However, these models are typically constructed manually using prior knowledge and can be over-reliant on study bias. These limitations hinder their ability to make accurate predictions and incorporate new evidence. Scaling up the construction of models to take advantage of increasingly abundant omics data can bridge these gaps by providing a comprehensive view of signalling events and how they influence cellular phenotypes. In this study, we present MAGELLAN, a method leveraging message passing graph neural networks to build computational models directly from pathway data and discrete rules representing experimental results. We used this to construct a computational model of breast cancer signalling and re-parameterize a previously published non-small cell lung cancer (NSCLC) model, showing that MAGELLAN can predict genetic dependencies and achieve comparable model quality to expert-curated and manually trained models. Our approach enables the integration of prior knowledge networks and experimental data to build predictive models that are mechanistically interpretable. This approach simplifies model creation, making it more accessible and practical for experimentalists, and supports broader applications in drug discovery and biological research.

systems biology↗

Predicting Personalised Therapeutic Combinations in Non-Small Cell Lung Cancer Using In Silico Modelling

The disease burden from non-small cell lung cancer (NSCLC) adenocarcinoma is substantial, with around a million new cases diagnosed globally each year, and a 5-year survival rate of less than 20%. A lack of therapeutic options personalized to individual patient genetics, and the targeted therapies that exist quickly succumbing to resistance, leads to high variation in survival. Patient stratification combined with greater personalisation of therapies have the potential to improve outcomes, however, the wide variation in mutations found in NSCLC adenocarcinoma patients mean that experimentally determining suitable treatment combinations is time-consuming and expensive. Here we present an in silico model encompassing tumour intrinsic key oncogenic signalling pathways, including EGFR, AKT, JAK/STAT and WNT for efficiently predicting rational drug-drug and drug-radiotherapy combination therapies in NSCLC. Using this model, we simulate diverse genetic profiles and test over 10,000 therapeutic combinations to identify optimal strategies to overcome resistance mechanisms specific to genetic profiles and p53 status. Our in silico model reproduces drug additivity experiments, predicts radio-sensitising genes validated in a CRISPR screen and identifies 53BP1 as a potential drug target that improves the therapeutic window during radiotherapy, as well as potential to use ATM inhibitors to overcome p53 loss-of-function driven radiotherapy resistance. We further use the in silico model to identify a 19-gene signature to stratify patients most likely to benefit from radiotherapy and validated this using TCGA data. These results further demonstrate the utility of in silico mechanistic modelling and present a bespoke computational resource for large-scale screening of personalised therapies applied to NSCLC.

cancer biology↗

Executable Network of SARS-CoV-2-Host Interaction Predicts Drug Combination Treatments

The COVID-19 pandemic has pushed healthcare systems globally to a breaking point. The urgent need for effective and affordable COVID-19 treatments calls for repurposing combinations of approved drugs. The challenge is to identify which combinations are likely to be most effective and at what stages of the disease. Here, we present the first disease-stage executable signalling network model of SARS-CoV-2-host interactions used to predict effective repurposed drug combinations for treating early- and late-stage severe disease. Using our executable model, we performed in silico screening of 9870 pairs of 140 potential targets and have identified 12 new drug combinations. Camostat and Apilimod were predicted to be the most promising combination in effectively supressing viral replication in the early stages of severe disease and were validated experimentally in human Caco-2 cells. Our study further demonstrates the power of executable mechanistic modelling to enable rapid pre-clinical evaluation of combination therapies tailored to disease progression. It also presents a novel resource and expandable model system that can respond to further needs in the pandemic.

systems biology↗

HOXA9 acts as a regulatory switch in acute myeloid leukaemia and myeloproliferative neoplasms

Blood malignancies arise from the dysregulation of haematopoiesis. The type of blood cell and the specific order of oncogenic events initiating abnormal growth ultimately determine the cancer subtype and subsequent clinical outcome. HOXA9 plays an important role in acute myeloid leukaemia (AML) prognosis by promoting blood cell expansion and altering differentiation; however, the function of HOXA9 in other blood malignancies is still unclear. Here, we demonstrate the importance of this gene in chronic myeloproliferative neoplasms (MPN) and highlight the biological switch and prognosis marker properties of HOXA9 in AML and MPN. This binary switch function can explain the clinical stratification of these two blood disorders. First, we establish the ability of HOXA9 to stratify AML patients with distinct cellular and clinical outcomes. Then, through the use of a computational network model of MPN, we show that the self-activation of HOXA9 and its relationship to JAK2 and TET2 can explain the branching progression of JAK2/TET2 mutant MPN patients towards divergent clinical characteristics. Finally, we predict a connection between the RUNX1 and MYB genes and a suppressive role for the NOTCH pathway in MPN diseases.

cancer biology↗